K
18.20
-0.33 (-1.78%)
Market Trend
Short Term | Medium Term | ||
Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
Stock | Kiniksa Pharmaceuticals, Ltd. | Bullish | Bullish |
Stockmoo Score
-0.6
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab. |
|
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Investment Style | Small Growth |
52 Weeks Range | ||
Price Target Range | ||
High | 40.00 (Jefferies, 119.78%) | Buy |
Median | 37.00 (103.30%) | |
Low | 34.00 (Wedbush, 86.81%) | Buy |
Average | 37.00 (103.30%) | |
Total | 2 Buy | |
Avg. Price @ Call | 25.78 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Jefferies | 13 Sep 2024 | 40.00 (119.78%) | Buy | 25.26 |
Wedbush | 23 Jul 2024 | 34.00 (86.81%) | Buy | 26.29 |
Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
---|---|---|---|---|
MEGNA MICHAEL R | - | 26.74 | -329 | -8,797 |
MOAT ROSS | - | 26.38 | -68,851 | -1,791,066 |
PAOLINI JOHN F. | - | 26.38 | -61,527 | -1,600,927 |
PATEL SANJ K | - | 26.74 | -3,177 | -84,953 |
RAGOSA MARK | - | 26.74 | -956 | -25,563 |
TESSARI EBEN | - | 26.74 | -577 | -15,429 |
Aggregate Net Quantity | -135,417 | |||
Aggregate Net Value ($) | -3,526,736 | |||
Aggregate Avg. Buy ($) | - | |||
Aggregate Avg. Sell ($) | 26.56 |
Name | Holder | Date | Type | Quantity | Price | Value ($) |
---|---|---|---|---|---|---|
MOAT ROSS | Officer | 03 Sep 2024 | Automatic sell (-) | 68,506 | 26.01 | 1,781,841 |
MOAT ROSS | Officer | 03 Sep 2024 | Option execute | 68,506 | - | - |
PAOLINI JOHN F. | Officer | 03 Sep 2024 | Automatic sell (-) | 60,692 | 26.01 | 1,578,599 |
PAOLINI JOHN F. | Officer | 03 Sep 2024 | Option execute | 60,692 | - | - |
MOAT ROSS | Officer | 02 Sep 2024 | Disposed (-) | 345 | 26.74 | 9,225 |
MOAT ROSS | Officer | 02 Sep 2024 | Option execute | 994 | - | - |
RAGOSA MARK | Officer | 02 Sep 2024 | Disposed (-) | 956 | 26.74 | 25,563 |
RAGOSA MARK | Officer | 02 Sep 2024 | Option execute | 1,861 | - | - |
TESSARI EBEN | Officer | 02 Sep 2024 | Disposed (-) | 577 | 26.74 | 15,429 |
TESSARI EBEN | Officer | 02 Sep 2024 | Option execute | 1,964 | - | - |
PATEL SANJ K | Officer | 02 Sep 2024 | Disposed (-) | 3,177 | 26.74 | 84,953 |
PATEL SANJ K | Officer | 02 Sep 2024 | Option execute | 6,569 | - | - |
PAOLINI JOHN F. | Officer | 02 Sep 2024 | Disposed (-) | 835 | 26.74 | 22,328 |
PAOLINI JOHN F. | Officer | 02 Sep 2024 | Option execute | 1,725 | - | - |
MEGNA MICHAEL R | Officer | 02 Sep 2024 | Disposed (-) | 329 | 26.74 | 8,797 |
MEGNA MICHAEL R | Officer | 02 Sep 2024 | Option execute | 775 | - | - |
Show more |
Date | Type | Details |
---|---|---|
28 Aug 2024 | Announcement | Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference |
23 Jul 2024 | Announcement | Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution |
16 Jul 2024 | Announcement | Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024 |
09 Jul 2024 | Announcement | Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sjögren’s Disease |
24 Jun 2024 | Announcement | Kiniksa Pharmaceuticals Partners with NHL Hall-of-Famer Henrik Lundqvist to Raise Awareness of Recurrent Pericarditis |
17 Jun 2024 | Announcement | Kiniksa Pharmaceuticals Sponsors American Heart Association’s Addressing Recurrent Pericarditis Initiative |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2024 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |